Cancer vaccines are the Holy Grail for patients and clinicians alike. The possibility that we can be vaccinated against common cancers is very appealing and the socioeconomic consequences are signifi cant. A recent paper published in the journal Nature Medicine suggests a new approach for the development of a prophylactic vaccine for breast cancer. Their strategy was to induce mammary gland failure in mice by immunisation with an antibody specifi c to a milk protein that resulted in autoimmunity during lactation. This also showed some effi cacy as a therapeutic vaccine. Can we look forward to the elimination of breast cancer?
Breast cancer is a very common disease, aff ecting approximately one in nine women in the western world at some time in their lives. In recent years, passive immunotherapy has become an eff ective adjunct for the treatment of HER2/neu-overexpressing breast cancers that often respond well to agents such as trastuzumab. Th is therapy is only eff ective, however, in a subset of breast cancers and patients with late-stage disease who are often immune suppressed are unlikely to respond. Furthermore, tumours can evolve to evade the immune response through regulatory T cells and myeloid suppressor cells [1, 2] . Th ere is therefore a need for a more globally eff ective, prophylactic vaccine.
Considerable eff ort has been directed towards this end, with limited success to date. A major problem with vaccine development is that the antigenic determinant ideally should be tumour specifi c. One such example is the glycoprotein mucin 1 (MUC-1), which is expressed by normal mammary epithelial cells. In cancer cells, however, the glycosylation pattern of MUC-1 is alteredrendering it antigenic [3] . Several promising MUC-1-based vaccines have been developed, although these have only been tested in a preclinical setting [4] . HER2 immunotherapy works because the density of the antigen is much higher in the cancer cells as a result of HER2 overexpression [5] .
Th e recent development of a prophylactic vaccine for cervical cancer [6] promises to save the lives of young women worldwide, particularly where screening pro grammes are unavailable. Breast cancer is much more likely to aff ect women than cervical cancer, and so the news that a prophylactic vaccine for breast cancer had been developed caused a media frenzy and was headline news.
Th e cause of all this excitement was a paper published in Nature Medicine by Jaini and coworkers [7] . Th eir approach was based on the hypothesis that removal of an organ will provide protection against cancer developing in that organ. Th is seems a simple, if somewhat dramatic, approach, and the breast is the only organ that perhaps could be induced to undergo catastrophic failure without severe consequences for the individual.
With this idea in mind, a protein specifi c for diff erentiated mammary epithelial cells was selected (αlactalbumin -a milk protein) and recombinant protein was used to immunise female mice. Interestingly, nonpregnant mice have few infl ammatory cells in their mammary tissue but lactating mice had infi ltrates of T cells and apparent lactation failure as pups failed to thrive, suggesting that the T cells had a cytotoxic eff ect. A more comprehensive follow-up of these animals would have provided reassurance that they did not suff er from detrimental eff ects arising from the extensive infl ammation in their mammary tissue, particularly since milk proteins are expressed in the gland with every oestrus cycle.
Th e next step was to test whether immunisation with α-lactalbumin could provide prophylactic protection against mammary cancer. Young mice harbouring an MMTV-Neu oncogene were therefore immunised, and tumour growth was then monitored after 8 months.
Although the numbers of mice are small, the vaccine was 100% eff ective. It would have been worthwhile following the immunised animals for longer to conclude that they did not develop cancer later. Nevertheless, these data suggest that immunisation can provide protection from breast cancer.
In a diff erent tumour model -transplanted 4T1 cellstumour growth was reduced in terms of size but not delayed in onset if immunisation occurred 13 days before tumour cell inoculation. Th e focus of the work then turned to the potential therapeutic ability of αlacatalbumin immunisation to inhibit the growth of already established tumours. Inoculation of 4T1 cells followed by immunisation decreased the eff ectiveness of the vaccine considerably, and a gap of 21 days between inoculation and immunisation resulted in no signifi cant protection. If the experiments had been continued for longer than 32 days, it seems very likely that there would be no real diff erence between the immunised mice and mock-immunised mice in terms of tumour burden.
Could this be an exciting prophylactic vaccine? In comparison with the vaccine for cervical cancer, which is primarily given to teenage girls, we suspect that most young women would not be willing to avoid lactation as the authors suggested -this is a natural consequence of pregnancy. Is it likely that women would not breast feed their infants in order to avoid a cancer that they have a 10% chance of developing 30 years later? Th is approach is therefore unlikely to be adopted as a prophylactic vaccine. Could it be useful for therapeutic purposes? Th at depends on the expression of α-lactalbumin by breast cancer cells, particularly the cancer-initiating (stem) cells, since eliminating the bulk of the tumour and not the cancer stem cells will not prevent recurrence of the tumour.
Whether α-lactalbumin is expressed in human breast cancers is not clear as the mRNA has not been identifi ed in breast cancer samples [8] and -as shown in this key publication by Hall and colleagues -there is a peptide that shares antigenic determinants with α-lactalbumin and with which antibodies to α-lactalbumin immunoreact. Bailey and colleagues, using a well-characterised antibody, could not detect α-lactalbumin in human breast cancers [9] , whilst it was present in pregnant breast and in lactational foci seen in normal virgin women taking oral contraceptives. Current data on αlactalbumin expression are based on contradictory data that are now nearly three decades old. Th ere is suffi cient uncertainty regarding the expression of α-lactalbumin in both the normal breast and breast cancers to question the validity of considering α-lactalbumin as a vaccine target in humans.
It is unfortunate that this preliminary study should be the subject of such unrealistic press coverage in such an emotive arena.
